MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. […]
Wall Street Beat
Senseonics sees activist investor take a major stake
Activist investor Sessa Capital has taken a sizeable stake in long-term, implantable CGM company Senseonics (NYSE: SENS), according to an SEC Schedule 13G filed today. The SEC filing lists Sessa directly owning 4,437,532 shares of Senseonics common stock, with warrants to buy another 8,000,000 shares of stock subject to a 9.9% blocker provision that prevents investors from […]
Embecta Q3 results beat analyst expectations
Julia Rock-Torcivia Embecta Corp. (Nasdaq: EMBC) raised its full-year outlook for adjusted earnings per share as third-quarter results beat analyst estimates. The medtech company, a BD spinoff that specializes in insulin delivery, reported last week net income of $21.1 million, or $0.36 per share, on revenue of $271.7 million for the three months ended June […]
ICU Medical Q2 results beat analyst expectations, driven by infusion systems
Julia Rock-Torcivia ICU Medical (Nasdaq: ICUI) reported second quarter results that beat Wall Street expectations, upping its full-year guidance. San Clemente, California–based ICE Medical, which specializes in IV therapy, infusion pumps and closed-system drug transfer devices, reported income of $19.1 million, or 76¢ per share, on revenue of $551.7 million for the three months ended June […]
Insulet slightly lowers 2026 sales growth outlook despite Q2 beats
Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates. The company previously projected total annual sales growth between 21% and 23%. However, it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth […]
Dexcom Q2 results beat expectations, lead to increased sales outlook
Dexcom (Nasdaq:DXCM) today reported second-quarter results that came in ahead of the consensus Wall Street forecast. Shares of DXCM rose 2% to $76.02 apiece after the market closed today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $249.1 million. That equals 64¢ per share on sales of $1.31 billion for the three […]
Beta Bionics posts Q2 beats on 38% sales growth
Beta Bionics (Nasdaq:BBNX) today reported second-quarter financial results that topped the consensus estimates on Wall Street. Shares of BBNX remained unmoved at $15.17 apiece after the market closed today. The Irvine, California-based automated insulin delivery technology developer reported losses of $23.4 million in the quarter. That equals 53¢ per share on sales of $32 million […]
Glucotrack, Lōkahi secure financing for completed merger
Glucotrack (Nasdaq:GCTK) announced today that it secured a bridge financing to support the completion of its merger with Lōkahi Therapeutics. The bridge financing, designed to support their strategic growth objectives, allows for the completion of the combination to proceed. Glucotrack did not disclose the terms of the financing. Earlier this week, the company’s announced their […]
MiniMed adds Abbott dual glucose-ketone sensor to portfolio, posts Q4 sales beat
MiniMed (Nasdaq:MMED) announced today that it expanded its agreement with Abbott (NYSE:ABT) to add more sensors to its portfolio. The company also announced fourth-quarter earnings results in tandem with the new Abbott integration. MiniMed has an existing partnership with Abbott through a collaboration between the companies agreed in 2024. They integrated Instinct, a sensor made by […]
Embecta completes Owen Mumford acquisition
Embecta (Nasdaq:EMBC) announced that it completed its previously announced acquisition of Owen Mumford Holdings Limited. Parsippany, New Jersey-based Embecta completed the deal on Friday, May 15. The former BD Diabetes business agreed to acquire Owen Mumford in March. The deal includes an upfront cash payment of approximately $133 million (£100 million). It also includes an […]
